Bristol Myers Squibb Breyanzi approved by USFDA for adults with Marginal Zone Lymphoma Ruchika Sharma5 Dec 2025 2:44 PM ISTPrinceton: Bristol Myers Squibb has received approval for Breyanzi (lisocabtagene maraleucel; liso-cel) from the U.S. Food and...
Bristol Myers Squibb Breyanzi secures European Commission nod for Mantle Cell Lymphoma Ruchika Sharma26 Nov 2025 11:30 AM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission has granted approval to Breyanzi (lisocabtagene maraleucel;...
Bristol Myers Squibb Breyanzi application accepted for priority review by USFDA for Marginal Zone Lymphoma Ruchika Sharma5 Aug 2025 12:20 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license...
USFDA approves label updates for Bristol Myers Squibb 2 CAR T cell therapies Ruchika Sharma29 Jun 2025 12:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR T...
USFDA lifts Risk Evaluation and Mitigation Strategies for CAR T cell therapies Ruchika Sharma28 Jun 2025 12:59 PM ISTThe U.S. Food and Drug Administration (USFDA) has announced that it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for currently...
Bristol Myers Squibb gets European Commission nod for Breyanzi for follicular lymphoma Ruchika Sharma16 March 2025 10:00 AM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has granted approval to Breyanzi (lisocabtagene...
Bristol Myers Squibb Breyanzi gets USFDA nod for Relapsed or Refractory Mantle Cell Lymphoma Ruchika Sharma31 May 2024 2:15 PM ISTPrinceton: Bristol Myers Squibb has announced the U.S. Food and Drug Administration (FDA) has granted approval for Breyanzi (lisocabtagene...
USFDA grants accelerated approval for Bristol Myers Squibb CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma Ruchika Sharma16 May 2024 2:30 PM ISTPrinceton: Bristol Myers Squibb has announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for...
Bristol Myers Squibb gets USFDA accelerated nod for Breyanzi as CAR T Cell Therapy for adults with relapsed or refractory chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Susmita Roy15 March 2024 12:32 PM ISTPrinceton: Bristol Myers Squibb has announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of...
EU regulator starts safety review of CAR-T cancer cell therapies Ruchika Sharma15 Jan 2024 9:00 AM ISTThe European Union's drug watchdog has said it had started a review into the safety risks associated with cancer cell therapies made by companies such...
Bristol Myers Squibb gets European Commission nod for CAR T Cell therapy Breyanzi for relapsed or refractory large B-cell lymphoma after one prior therapy Ruchika Sharma5 May 2023 2:30 PM ISTBreyanzi is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.
Bristol Myers Squibb gets positive EMA Committee opinion for Breyanzi for Relapsed or Refractory Large B-cell Lymphoma after one prior therapy Ruchika Sharma2 April 2023 10:00 AM ISTBreyanzi is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.
